A new, minimally invasive treatment that tears microscopic holes in tumors without harming healthy tissue is a promising treatment for challenging cancers, suggests a preliminary study being presented at the Society of Interventional ...
Apr 14, 2013
0
0
Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association ...
Apr 9, 2013
0
0
The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
Mar 27, 2013
0
0
Two years after Japan's nuclear plant disaster, an international team of experts said Thursday that residents of areas hit by the highest doses of radiation face an increased cancer risk so small it probably won't be detectable.
Feb 28, 2013
0
0
The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering ...
Feb 14, 2013
0
0
A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs together ...
Jan 8, 2013
0
0
As many as 50 percent of all human protein-coding genes are regulated by microRNA (miRNA) molecules. While some miRNAs impact onset and progression of cancer, others can actually suppress the development of malignant tumors ...
Dec 19, 2012
0
0
The most comprehensive study of potential World Trade Center-related cancers raises more questions than it answers and won't end a debate over whether the attacks were really a cause.
Dec 18, 2012
0
0
The number of people diagnosed with thyroid cancer in England has doubled since the early 1990s, according to a new report published by the National Cancer Intelligence Network (NCIN) today (Friday).
Dec 14, 2012
0
0
(HealthDay)—Cometriq (cabozantinib) has been approved by the U.S. Food and Drug Administration to treat modullary thyroid cancer that has spread to other parts of the body, the agency said Thursday.
Nov 29, 2012
0
0
